Key result
Jun13133 mitigates paralysis, prevents weight loss, and reduces viral replication in EV-D68 mouse models.
Why the study?
No approved vaccine or antiviral is available for Enterovirus D68, which can cause severe neurological disease including acute flaccid myelitis.
Jun13133 is a promising lead compound that demonstrates in vivo efficacy against EV-D68-induced neurological disease in a mouse model.
Answers are grounded in this paper and cite their sources.
Provides preclinical support for EV-D68 3Cpro inhibition; leaves open translation to clinical efficacy.
Enterovirus D68 (EV-D68) is a non-polio enterovirus that primarily causes respiratory illness but can also lead to severe disease, including acute flaccid myelitis. No approved vaccine or antiviral is available. Here, we report the rational design and structure−property optimization of dipeptidyl EV-D68 3C protease (3Cpro) inhibitors. Structure-guided optimization and prodrug modification identified Jun13133 as a potent antiviral active against multiple contemporary EV-D68 isolates and EV-A71, with high selectivity. Computational modeling supported a stable substrate-mimetic binding mode consistent with reported covalent 3Cpro inhibitors. Jun13133 also showed favorable in vivo pharmacokinetic properties. In a neonatal mouse model of EV-D68-induced neurological disease, Jun13133 mitigated paralysis, prevented weight loss, and reduced viral replication in spinal cord and muscle tissues. These results validate EV-D68 3Cpro as a druggable antiviral target and support Jun13133 as a promising lead for further development.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) studied Enterovirus D68 infection. Jun13133 was evaluated on Paralysis, weight loss, and viral replication. Jun13133 mitigated paralysis, prevented weight loss, and reduced viral replication in spinal cord and muscle tissues in a neonatal mouse model of EV-D68-induced neurological disease.
Synapse has enriched 10 related papers. Consider them for comparative context: